And for Professor Thomas Shea of UMass Lowell, "it" is the winning of a significant patent for his brainchild, PERCEPTIV - an over-the-counter pill that protects against cognitive decline due to aging.
The so-called "composition and methods" patent, U.S. 8,597,640, was announced by the U.S. Patent Office on Dec. 3.
Put simply, it recognizes and protects PERCEPTIV's exact ingredients and their formulations, as well as what PERCEPTIV can do - offer neuro protection that improves cognitive performance.
Shea, who credited a former student, Amy Chan-Daniels, who did clinical work as part of her doctoral thesis, has been researching brain health and cognitive performance for more than 20 years.
Prusaczyk said his company's positioning is "pretty unique," in that Shea
and his team did virtually all of the patent-application work.
The work was done independently, with Dr. Shea
as the lead inventor.
For Shea, a cell biologist who is director of UMass Lowell's Center for Cellular Neurobiology and Neurodegeneration Research, finding a solution to brain degeneration was inspired by working at McLean Hospital in Belmont with people experiencing cognitive decline.
"We donated time, and involved lots of people across the country, and they were lucky to get lunch money," Shea
"We had 11 sites for clinical studies, no salaries.
It was academic people who love this work."
PERCEPTIV consists of a precise blend of three vitamins (folate, B12 and vitamin E) and three nutraceuticals (S-adenosyl methionine, N-Acetyl cysteine and acetyl-L-carnitine) that offer antioxidant protection to brain cells and a way to maintain brain-cell health and function.
seven independent studies have been published in scientific journals and presented at multiple international conferences, including the Alzheimer's
Association International Conferences in Paris and Boston.
"Not a dime corporate-funded," Shea
said, adding that the product was "signed, sealed and delivered" once Sevo
agreed to license it."